Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: Results of intergroup 0159, cancer and leukemia group B 9480

Journal of Clinical Oncology

Volumn 20, Issue 16, 2002, Pages 3369-3375

  Small, Eric J ^a   Halabi, Susan ^a   Ratain, Mark J ^a   Rosner, Gary ^a   Stadler, Walter ^a   Palchak, David ^a   Marshall, Ernest ^a   Rago, Randall ^a   Hars, Vera ^a   Wilding, George ^a   Petrylak, Daniel ^a   Vogelzang, Nicholas J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SURAMIN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DYSPNEA; EDEMA; FATIGUE; GASTROINTESTINAL TOXICITY; HEART DISEASE; HUMAN; HYPOKALEMIA; LEUKEMIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MOTOR NEURON DISEASE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; WEIGHT REDUCTION;

AGED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURAMIN; SURVIVAL RATE;

EID: 0037102220     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.10.022     Document Type: Article

References (21)

1. Cancer Statistics, 2001
2. Second-line hormonal therapy for advanced prostate cancer: A shifting paradigm
3. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma
4. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?
5. Suramin: Defining the role in the clinic
6. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer
7. Development and validation of a pharmacokinetically based fixed dosing scheme for suramin
8. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer
9. Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer
10. Suramin and hydrocortisone: Determining drug efficacy in androgen-independent prostate cancer
11. Suramin in hormone-refractory metastatic prostate cancer: A drug with limited efficacy
12. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: Results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone
13. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group
14. Discrete sequential boundaries for clinical trials
15. Nonparametric estimation from incomplete observations
16. Analysis of survival by tumor response
17. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer
18. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer
19. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy
20. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: Association with progression-free survival, pain end points, and survival
21. Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases